Woippy, March 4th, 2024 – ABL Diagnostics (FR001400AHX6), a leading molecular diagnostics company, has announced today that its parent company, Advanced Biological Laboratory (ABL), has conducted three block transactions since August 2023, resulting in the sale of 59,651 shares of its common stock. These transactions have been reported to ONDE, the central information filing system of the Autorité des Marchés Financiers (AMF) and are publicly available on the AMF’s decisions and notifications database website (https://bdif.amf-france.org/en).
ABL Diagnostics’ parent company, ABL, is a privately held company based in Luxembourg and currently holds over 99% of the shares of ABL Diagnostics.
According to Mr. Ronan Boulmé, GRC Director of the ABL Group, these transactions represent 0.37% of the total of common shares and are in line with ABL’s commitment to the AMF to create a free float of ABL Diagnostics shares by selling up to 30% of its common shares. He added that this goal continues to be pursued with several ongoing efforts and partnerships. The recent block trades mark the beginning of a strategic journey for ABL Diagnostics as it enters its next phase of growth and development. These investments will fuel ABL Diagnostics’ efforts to deliver innovative diagnostic solutions in collaboration with strategic partners globally.
ABL Diagnostics is a worldwide leading international company that offers innovative and proprietary molecular biology assays and solutions for molecular detection and genotyping. Its products include Polymerase Chain Reaction (PCR) assays under the UltraGene® brand and DNA sequencing solutions under the DeepChek® brand. These products generate recurring revenues and cover one of the largest portfolios of microbiology applications, with a primary focus on HIV, SARS-CoV-2, Tuberculosis, viral hepatitis B and C, and other viral and bacterial targets.
The company’s products are marketed globally through its own sales team and a network of exclusive distributors. Its clients include academic clinical pathology labs, private reference labs, and researchers looking to implement innovative and robust microbiology content in their work. ABL Diagnostics also develops, manufactures, and markets kits for clinical specimen collection under the MediaChek® brand, as well as digital solutions such as Nadis®, a CE-marked Electronic Medical Record (EMR) system used in over 200 hospitals in France.
ABL Diagnostics is a publicly traded company listed on Euronext’s regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6) and is headquartered in Woippy.
For more information, please visit www.abldiagnostics.com.
Contact information:
ABL Diagnostics
info@abldiagnostics.com
Dr. Chalom Sayada, CEO and Founder of ABL SA and Board Director of ABLD
Tel: + 33 (0)7 83 64 68 50
Forward-looking statements:
This press release contains forward-looking statements concerning ABL Diagnostics and its business. These statements are based on assumptions that ABL Diagnostics considers to be reasonable, but there can be no assurance that they will be verified. These statements are subject to numerous risks, including those set forth in the “Risk Factors” section of the universal registration document filed with the AMF on July 12, 2022, under number 22-296, available on ABL Diagnostics’ website (www.abldiagnostics.com) and are also subject to changes in economic conditions, financial markets, and the markets in which ABL Diagnostics operates. The occurrence of any of these risks could cause actual results, financial conditions, performance, or achievements of ABL Diagnostics to be materially different from the forward-looking statements.
This press release and the information contained herein do not constitute an offer or invitation to sell or subscribe to ABL Diagnostics shares. The distribution of this press release in certain countries may be restricted by law, and individuals in possession of this press release must comply with any local restrictions.
Distributed by https://pressat.co.uk/
